Overview

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to combine AZD1775 with standard front-line chemotherapy in subjects with advanced NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Adavosertib
Carboplatin
Pemetrexed